HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma

BACKGROUND: Sorafenib significantly improves survival in patients with advanced hepatocellular carcinoma (HCC). This phase IV study assessed sorafenib efficacy/safety in Taiwanese patients with advanced HCC and Child–Pugh A status. METHODS: All patients received 400 mg sorafenib BID. Safety, efficac...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hepatol Int
Autori principali: Lin, Shi-Ming, Lu, Sheng-Nan, Chen, Ping-Tsung, Jeng, Long-Bin, Chen, Shinn-Cherng, Hu, Chi-Tan, Yang, Sien-Sing, Le Berre, Marie-Aude, Liu, Xuan, Mitchell, David Y., Prins, Klaas, Grevel, Joachim, Peña, Carol A. E., Meinhardt, Gerold
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer India 2016
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5362674/
https://ncbi.nlm.nih.gov/pubmed/27909950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12072-016-9774-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi